Doctors ought to take into consideration whether their sufferers with underlying NAION hazard aspects could be adversely afflicted by use of PDE5 inhibitors. Individuals who have currently professional NAION are at greater threat of NAION recurrence. Consequently, PDE5 inhibitors, such as LEVITRA, must be employed with caution in these people and o